IBRX today
$6.67-$0.08 (-1.11%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minStrong Bearish
5 minLeaning Bullish
Daily trend turns down below $5.54
Key levels
Resistance$7.93
Resistance$6.70
Support$5.58
Support$1.95
Latest news & SEC filings
EarningsImmunityBio posts wider loss for the quarter
EarningsImmunityBio posts third-quarter 2026 results, cites regulatory progress
All IBRX news →About ImmunityBio
ImmunityBio is a biotechnology company that creates treatments designed to help a patient's immune system fight cancer and infectious diseases. Its main product, ANKTIVA, is a fusion protein that boosts immune cells and is approved for a type of bladder cancer that no longer responds to standard therapy, and in some countries for a form of lung cancer. The company also works on viral-vector vaccines and natural killer cell therapies, serving healthcare providers and patients in the United States, Europe, the United Kingdom, and the Middle East.
Based on the company's 10-K filed Feb 23, 2026.
Nasdaq · Healthcare
ImmunityBio, Inc. (IBRX)
What Is the Price Target for IBRX?
SEPT Low Target
$14.00
SEPT Mid Target
$14.50
SEPT High Target
$15.00
Analyst Consensus
$14.50
Is IBRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 668.3% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IBRX.
Start Free Trial →Is IBRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$14.50
34
Moat Score
NONE
5/9
Piotroski Score
-6.8
Altman Z-Score
What Is Smart Money Doing with IBRX?
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
BUYING
2 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Simon Barry J. | director | Sale | 25,000 | $269K | Oct 5, 2026 |
| Cohen Cheryl | director | Buy | 55,979 | $167K | Oct 2, 2026 |
| Cohen Cheryl | director | Sale | 81,056 | $851K | Oct 2, 2026 |
| Simon Barry J. | director | Sale | 23,033 | $165K | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IBRX Growth Story
Revenue YoY
668.3%
3yr Revenue CAGR
678.6%
EPS Growth YoY
38.71%
FCF Growth YoY
22.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for IBRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IBRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:48:55 | $6.63 | 2,928 | $$19K | SELL |
| 24:34:36 | $6.64 | 2,500 | $$17K | SELL |
| 23:31:53 | $6.66 | 1,000 | $$7K | SELL |
| 23:28:09 | $6.66 | 2,000 | $$13K | SELL |
| 23:21:28 | $6.65 | 1,500 | $$10K | SELL |
5 dark pool trades shown · $$66K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for IBRX
PREVIEWSEPT Investing provides real-time options flow tracking for IBRX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $10 | Jan 15 | 65 | $$35 | 1 | SWEEP |
| CALL | $6.5 | Nov 13 | 2 | $$1155 | 33 | SWEEP |
| CALL | $7 | Nov 19 | 373 | $$32.3K | 154 | BLOCK |
| CALL | $22 | Jan 21 | 436 | $$65 | 1 | SWEEP |
| CALL | $22 | Jan 21 | 436 | $$65 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ImmunityBio, Inc. (IBRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (9 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IBRX — frequently asked questions
What is IBRX stock price today?
ImmunityBio, Inc. (IBRX) is at $6.67, down 1.11% (-$0.08) at the Nov 11, 2026 close.
Why is IBRX stock moving today?
Latest IBRX news — Nov 9, 2026: ImmunityBio posts wider loss for the quarter · Nov 9, 2026: ImmunityBio posts third-quarter 2026 results, cites regulatory progress
Why did IBRX stock move on Nov 9, 2026?
ImmunityBio shares fell 1.52% to close at $7.11 after the company reported a wider-than-expected third-quarter adjusted loss of $0.09 per share versus the $0.08 loss consensus, with revenue of $48.841 million missing the $59.250 million estimate. The stock traded in a wide range on heavy volume of over 41.6 million shares, dipping as low as $6.36 before recovering.
What is the IBRX price target?
The average analyst price target for IBRX is $14.50, ranging from $14 to $15, based on 2 analysts. Latest: Jefferies maintains on Oct 15, 2026.
What do analysts rate IBRX?
Analyst ratings for IBRX: 4 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did IBRX beat earnings?
IBRX last reported on Nov 10, 2026: EPS -$0.09 vs -$0.08 expected — a miss of 12.5%.
Does IBRX pay a dividend?
IBRX does not currently pay a dividend.
What are IBRX support and resistance levels?
Support: $5.58, $1.95. Resistance: $6.70, $7.93, $8.95.
What are insiders doing with IBRX?
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
What is the latest news on IBRX?
Nov 9, 2026: ImmunityBio posts wider loss for the quarter · Nov 9, 2026: ImmunityBio posts third-quarter 2026 results, cites regulatory progress